This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Salix Pharmaceuticals in $300M Acquisition of Oceana Therapeutics

November 10, 2011

WASHINGTON, DC, November 10, 2011 — Covington & Burling represented Salix Pharmaceuticals, Ltd. in its agreement to acquire Oceana Therapeutics, Inc., a privately held global provider of gastroenterology and urology therapeutics, for $300 million in cash.

“The acquisition of Oceana expands our product portfolio of innovative products, furthers the diversification of Salix’s base business and provides immediate added revenue,” said Carolyn Logan, president and CEO of Salix. The transaction is expected to close in December 2011, subject to customary conditions of closing, including U.S. antitrust approval.

Salix, headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases.

The Covington team, based in Washington, New York and London, was led by corporate partners Ed Britton and Catherine Dargan with associates James Wawrzyniak, Grant Young, and Caitlin Cottingham*. Also advising on the deal were Robert Heller and Sarah Burnham (tax), Michael Francese and Michael Chittenden (employee benefits), Heather Haberl (real estate), Scott Danzis, Chris Pruitt and Robin Blaney (food & drug), Natalie Derzko and Kathleen Gallagher-Duff (intellectual property), Marialuisa Gallozzi (insurance) and James Dean (antitrust).

*Admitted to the New York bar; not admitted to practice in Washington.

Share this article: